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Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and
Food Allergens (NDA) was asked to deliver a scientific opinion on a botanical extract derived from both
Panax notoginseng and Astragalus membranaceus (AstraGinTM) as a novel food (NF) pursuant to
Regulation (EU) 2015/2283. The NF is a combination of an ethanol extract of the roots of
A. membranaceus and a hot water extract of the roots of P. notoginseng. The NF contains 1.5–5%
total saponins, 0.1–0.5% ginsenoside Rb1 and 0.01–0.1% astragaloside I. Both plants that are used to
produce the NF have a long history of use, especially in traditional Chinese medicine. Information on
the production process and the composition of the NF is sufficient and does not raise safety concerns.
The applicant proposed to use the NF as a food supplement for the general adult population, excluding
pregnant women, at a maximum daily amount of 350 mg. Taking into account these conditions of use,
the Panel considers that the consumption of the NF is not nutritionally disadvantageous. The provided
genotoxicity studies do not raise concerns for genotoxicity of the NF. Based on the findings of a
subchronic toxicity study, supported by a subacute toxicity study, the Panel identified the overall no
observed adverse effect level (NOAEL) of the NF at 100 mg/kg body weight (bw) per day. By applying
an uncertainty factor of 200, the Panel concludes that the NF is safe at an intake level of 0.5 mg/kg
bw per day, corresponding to a maximum daily intake of 35 mg of the NF for the target population,
i.e. adults excluding pregnant women.
© 2020 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
Keywords: Panax notoginseng, Astragalus membranaceus, Astragalus propinquus, extract, novel
food, safety
Requestor: European Commission following an application by NuLiv Science
Question number: EFSA-Q-2018-00557
Correspondence: nda@efsa.europa.eu
EFSA Journal 2020;18(5):6099www.efsa.europa.eu/efsajournal
Panel members: Dominique Turck, Jacqueline Castenmiller, Stefaan De Henauw, Karen Ildico Hirsch-
Ernst, John Kearney, Helle Katrine Knutsen, Alexandre Maciuk, Inge Mangelsdorf, Harry J McArdle,
Androniki Naska, Carmen Pelaez, Kristina Pentieva, Alfonso Siani, Frank Thies, Sophia Tsabouri and
Marco Vinceti.
Suggested citation: EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens),
Turck D, Castenmiller J, De Henauw S, Hirsch-Ernst KI, Kearney J, Maciuk A, Mangelsdorf I, McArdle
HJ, Naska A, Pelaez C, Pentieva K, Siani A, Thies F, Tsabouri S, Vinceti M, Cubadda F, Engel KH,
Frenzel T, Heinonen M, Marchelli R, Neuh€auser-Berthold M, Poulsen M, Schlatter JR, van Loveren H,
Ackerl R and Knutsen HK, 2020. Scientific Opinion on the safety of a botanical extract derived from
Panax notoginseng and Astragalus membranaceus (AstraGinTM) as a novel food pursuant to
Regulation (EU) 2015/2283. EFSA Journal 2020;18(5):6099, 16 pp. https://doi.org/10.2903/j.efsa.
2020.6099
ISSN: 1831-4732
© 2020 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License,
which permits use and distribution in any medium, provided the original work is properly cited and no
modifications or adaptations are made.
The EFSA Journal is a publication of the European Food
Safety Authority, an agency of the European Union.
Safety of AstraGinTM as a novel food
www.efsa.europa.eu/efsajournal 2 EFSA Journal 2020;18(5):6099
Table of contents
Abstract................................................................................................................................................... 1
1. Introduction................................................................................................................................. 4
1.1. Background and Terms of Reference as provided by the European Commission ................................ 4
2. Data and methodologies ............................................................................................................... 4
2.1. Data............................................................................................................................................ 4
2.2. Methodologies.............................................................................................................................. 4
3. Assessment.................................................................................................................................. 4
3.1. Introduction................................................................................................................................. 4
3.2. Identity of the NF......................................................................................................................... 5
3.2.1. Panax notoginseng (Burkill) F.H. Chen............................................................................................ 5
3.2.2. Astragalus membranaceus (Fisch.) Bunge....................................................................................... 5
3.3. Production process ....................................................................................................................... 5
3.4. Compositional data....................................................................................................................... 6
3.4.1. Stability ....................................................................................................................................... 7
3.5. Specifications ............................................................................................................................... 8
3.6. History of use of the NF and/or of its source .................................................................................. 9
3.6.1. History of use of the source of the NF ........................................................................................... 9
3.6.2. History of use of the NF................................................................................................................ 9
3.7. Proposed uses and use levels ........................................................................................................ 9
3.7.1. Target population ......................................................................................................................... 9
3.7.2. Proposed uses and use levels ........................................................................................................ 9
3.8. Absorption, distribution, metabolism and excretion (ADME) ............................................................. 9
3.9. Nutritional information .................................................................................................................. 9
3.10. Toxicological information............................................................................................................... 10
3.10.1. Genotoxicity................................................................................................................................. 10
3.10.2. Subacute and subchronic toxicity................................................................................................... 11
3.10.3. Human data................................................................................................................................. 13
3.11. Allergenicity ................................................................................................................................. 13
4. Discussion ................................................................................................................................... 13
5. Conclusions.................................................................................................................................. 13
Steps taken by EFSA ................................................................................................................................ 13
References............................................................................................................................................... 14
Abbreviations ........................................................................................................................................... 15
Safety of AstraGinTM as a novel food
www.efsa.europa.eu/efsajournal 3 EFSA Journal 2020;18(5):6099
1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
On 8 June 2018, the company NuLiv Science submitted a request to the European Commission in
accordance with Article 10 of Regulation (EU) 2015/22831 to place a botanical extract derived from both
Panax notoginseng and Astragalus membranaceus (AstraGinTM) on the Union market as a novel food (NF).
The NF is intended for use in food supplements and the suggested daily intake for adults is 50 mg.
The target population is the general population, excluding children and pregnant women.
On 22 October 2018, and in accordance with Article 10(3) of Regulation (EU) 2015/2283, the
European Commission asked EFSA to provide a scientific opinion on the extract derived from Panax
notoginseng and Astragalus membranaceus.
2. Data and methodologies
2.1. Data
The safety assessment of this NF is based on data supplied in the application, information provided
by the EFSA Working Group on Compendium of Botanicals and information submitted by the applicant
following two EFSA requests for supplementary information.
The information in support of this application has been made available through the Commission
e-submission portal (NF 2018/0284).
Administrative and scientific requirements for NF applications referred to in Article 10 of Regulation
(EU) 2015/2283 are listed in the Commission Implementing Regulation (EU) 2017/24692.
A common and structured format on the presentation of NF applications is described in the EFSA
guidance on the preparation and presentation of a NF application (EFSA NDA Panel, 2016). As
indicated in this guidance, it is the duty of the applicant to provide all of the available (proprietary,
confidential and published) scientific data, including both data in favour and not in favour of
supporting the safety of the proposed NF.
This NF application includes a request for protection of proprietary data in accordance with Article
26 of Regulation (EU) 2015/2283. Data claimed to be proprietary by the applicant include all the
submitted analytical information, the manufacturing process and the toxicity studies provided.
2.2. Methodologies
The assessment follows the methodology set out in the EFSA guidance on NF applications (EFSA NDA
Panel, 2016) and the principles described in the relevant existing guidance documents from the EFSA
Scientific Committee. The legal provisions for the assessment are laid down in Article 11 of Regulation
(EU) 2015/2283 and in Article 7 of the Commission Implementing Regulation (EU) 2017/2469.
The information provided by the EFSA Working Group on Compendium of Botanicals is based on
extensive literature searches on P. notoginseng and A. membranaceus, following a search strategy and
standard operating procedure as described by the University of Chemistry and Technology (UCT) of
Prague (UCT, 2020).
This assessment concerns only risks that might be associated with consumption of the NF under
the proposed conditions of use, and is not an assessment of the efficacy of AstraGinTM with regard to
any (claimed) benefit.
3. Assessment
3.1. Introduction
The NF which is the subject of the application is a combination of root extracts from P. notoginseng
and A. membranaceus, denominated as AstraGinTM.
1 Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods, amending Regulation (EU) No 1169/2011
of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the European Parliament and of the
Council and Commission Regulation (EC) No 1852/2001 (2013/0435 (COD). OJ L 327, 11.12.2015, p. 1–22.
2 Commission Implementing Regulation (EU) 2017/2469 of 20 December 2017 laying down administrative and scientific
requirements for applications referred to in Article 10 of Regulation (EU) 2015/2283 of the European Parliament and of the
Council on novel foods. OJ L 351, 30.12.2017, pp. 64–71.
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The NF falls under Regulation 2015/2283, Article 3(2)(a)(iv): food consisting of, isolated from or
produced from plants or their parts of.
The NF is proposed by the applicant to be used as a food supplement for the general adult
population, except pregnant women.
3.2. Identity of the NF
The NF is a combination of an ethanol extract of the roots of A. membranaceus (Fisch.) Bunge and
a hot water extract of the roots of P. notoginseng (Burkill) F.H. Chen.
3.2.1. Panax notoginseng (Burkill) F.H. Chen
The full taxonomy of P. notoginseng is the following. Kingdom: Plantae, Division: Magnoliophyta,
Class: Magnoliopsida, Order: Apiales, Family: Araliaceae, Genus: Panax, Species: Panax notoginseng.
The plant is also known as Panax pseudoginseng var. notoginseng (Burkill) G. Hoo & C.L. Tseng
and by a number of traditional Chinese names, e.g. Sanqi, San Qi, Shan Qi, Tu San Qi, Tianqi and
Tien-chi.
The plant belongs to the genus Panax, which includes about 15 species from both Asia and
America. Analyses of the 5S-rRNA spacer domains from seven Panax species showed a high degree of
genetic similarity with ~ 75% of the spacer domains conserved throughout the genus (Cui et al.,
2003).
The root of P. notoginseng contains ~ 8–13% saponins by weight (Dong et al., 2003; Wang et al.,
2006). More than 150 saponins, mostly of dammarane type with 20(S)-protopanaxadiol or 20(S)-
protopanaxatriol aglycon moieties have been identified in this species, some of them being present in
other Panax species, some being specific of P. notoginseng. Many other compounds of various
chemical classes are found including flavonoids, cyclopeptides, sterols, polyacetylenes, a volatile oil,
saccharides and amino acids (Wang et al., 2016). Based on an earlier review, the applicant stated that
56 saponins of P. notoginseng have been identified with major ones being ginsenosides Rb1, Rd, Re
and Rg1. Five polyacetylenes have been identified, i.e. panaxytriol, panaxydol, notoginsenic acid, b-
sophoroside and 10-hydroxydeca-4,6-diynoic acid. The extract also contained the flavonoids quercetin
and quercetin-3-O-sophoroside, a number of phytosterols and amino acids, the most prevalent ones
being arginine, aspartic acid and glutamic acid. The non-proteinogenic amino acid L-dencichin
(oxalyldiaminopropionic acid) has also been identified (Wang et al., 2006).
3.2.2. Astragalus membranaceus (Fisch.) Bunge
The name A. membranaceus (Fisch.) Bunge is a synonym of the accepted name Astragalus
propinquus Schischkin.3
The full taxonomy of A. membranaceus/A. propinquus is the following. Kingdom: Plantae, Division:
Magnoliophyta, Class: Magnoliopsida, Order: Fabales, Family: Fabaceae, Genus: Astragalus, Species:
A. membranaceus/A. propinquus.
The plant is also known as milkvetch root (English), ogi (Japanese), hwanggi (Korean) and huang
qi (in Traditional Chinese Medicine).
This species is defined as Radix Astragali in the Pharmacopoeia of China (Fu et al., 2014).
The root of A. membranaceus/A. propinquus contains a number of saponins, in particular
cycloartane triterpene glycosides (astragalosides I–VII) as well as flavonoids (calycosin and
formononetin genins and glycosides, ononin, among others). Other constituents include c- and a-
aminobutyric acids, L-canavanine, choline, betaine, gluconic acid, linoleic acid, asparagine, b-sitosterol
(Thorne Research Inc, 2003; Fu et al., 2014).
3.3. Production process
According to the information provided, the NF is produced under adherence to good manufacturing
practice (GMP) at GMP-certified manufacturing facilities in China. Information was provided on the
Hazard Analysis and Critical Control Points (HACCP) scheme applied.
The A. membranaceus roots are purchased from growers in Gansu and Inner Mongolia provinces in
the north-western region of China while the P. notoginseng roots are acquired from growers in Yunnan
and Sichuan provinces in the southern region of China.
3 http://www.theplantlist.org/tpl1.1/record/ild-32156
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The roots of both plants are washed with water, dried and pulverised.
The pulverised roots of A. membranaceus are then passed through a 10-mesh size sieve and
extracted with eightfold volume of 40% ethanol. The extract is centrifuged, filtered, concentrated/
dried, smashed and screened through an 80-mesh size sieve. The extract is analysed for the content
of total saponins (by ultraviolet (UV) spectrophotometry) and for astragaloside I (by high-performance
liquid chromatography-evaporative light scattering detection (HPLC-ELSD)).
The pulverised roots of P. notoginseng are passed through a 20-mesh size sieve and extracted with
10-fold volume of water. The extract is centrifuged, filtered and concentrated. The concentrated
solution is subsequently absorbed on a resin, which is washed with water, and eluted with 60%
ethanol. The eluent is concentrated/dried, smashed and screened through an 80-mesh size sieve. The
extract is analysed for the content of total saponins (by UV spectrophotometry) and for ginsenoside
Rb1 (by HPLC-UV).
The plant to extract ratios were indicated by the applicant to be 10:1 for the Astragalus extract and
50:1 for the Panax extract.
At the end of the manufacturing process the extracts are mixed (45–47.5% of each extract) with
maltodextrin (5–10%). The blend, i.e. the NF, is analysed for the marker compounds (total saponins,
ginsenoside Rb1 and astragaloside I; see the following Section), physicochemical characteristics, heavy
metals, pesticides, organic solvent residue and microbial counts before packaging into plastic bags for
storage.
The Panel considers that the production process is sufficiently described and does not raise safety
concerns.
3.4. Compositional data
As described in the previous section, the NF is a blend of an ethanol extract of the roots of
A. membranaceus and a hot water extract of the roots of P. notoginseng (plus maltodextrin as an
excipient). The NF contains 1.5–5% total saponins, 0.1–0.5% ginsenoside Rb1 and 0.01–0.1%
astragaloside I.
In order to provide information on the variability of the composition of the NF, the applicant
submitted batch to batch analyses for total saponins, ginsenoside Rb1, astragaloside I, proximates, a
number of organoleptic and physicochemical parameters, contaminants and microbiological quality of
the NF (Table 1).
Table 1: Batch-to-batch analyses of the NF
Parameter
Batch number
C20151209 C20160606(1) C20170106 C20170515 C20171009
Total saponins 4.10% 3.79% 3.12% 3.56% 3.09%
Ginsenoside Rb1 0.10% 0.17% 0.14% 0.11% 0.10%
Astragaloside I 0.034% 0.028% 0.028% 0.024% 0.048%
Colour Light yellow Light yellow Light yellow Light yellow Light yellow
Odour ‘Characteristic’ ‘Characteristic’ ‘Characteristic’ ‘Characteristic’ ‘Characteristic’
Appearance Fine powder Fine powder Fine powder Fine powder Fine powder
Sieve analysis 100% through
80 mesh
99% through 80
mesh
100% through
80 mesh
100% through
80 mesh
100% through
80 mesh
Total carbohydrates 91.8% 92.2% 92.1% 92.4% 89.6%
Protein 2.1% 2.5% 2.4% 2.5% 4.3%
Fat 1.4% 0.8% 0.7% 0.7% 1.1%
Moisture 4.3% 4.1% 4.5% 4.2% 4.6%
Ash 0.4% 0.4% 0.3% 0.3% 0.4%
Bulk density 0.59 g/mL 0.54 g/mL 0.56 g/mL 0.55 g/mL 0.53 g/mL
Solubility in water
(1 g in 30 mL)
Soluble Soluble Soluble Soluble Soluble
Contaminants
Lead (Pb) < 0.1 mg/kg < 0.1 mg/kg < 0.1 mg/kg < 0.1 mg/kg < 0.1 mg/kg
Arsenic (As) 0.19 mg/kg < 0.1 mg/kg < 0.1 mg/kg < 0.1 mg/kg < 0.1 mg/kg
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For four additional batches (Table 2) information on the content of total saponins was provided,
plus for three of the four batches also the concentrations of astragaloside I and ginsenoside Rb1.
In order to achieve a certain concentration of total saponins and ginsenoside Rb1 and astragaloside
I in the NF, the applicant established internal specifications for the two extracts, with total saponins
≥ 0.6% and ginsenoside Rb1 ≥ 0.2% for the P. notoginseng extract, and total saponins ≥ 3% and
astragaloside I ≥ 0.02% for the A. membranaceus extract.
Considering that the genus Astragalus is known to accumulate trace elements, the applicant provided
a certificate of analysis for one batch of the NF, in which selenium, thallium and uranium were below
detection limits (i.e. < 0.1 mg/kg for selenium and thallium and < 0.01 mg/kg for uranium).
Additionally, the applicant provided the analytical results for the concentrations of pesticides and
mycotoxins in the NF, which were all below their limits of detection (LODs).
The Panel considers that the information provided on the composition of the NF including the batch
to batch variability is sufficient and does not raise safety concerns.
3.4.1. Stability
The applicant proposes a shelf-life of 3 years from the time of manufacturing of the NF.
The applicant provided data of a 6 months accelerated (i.e. at 40°C and 75% relative humidity)
stability testing performed with three batches of the NF. The batches were analysed for the content of
total saponins in the NF, which remained stable throughout the testing period (Table 3). Further
parameters were appearance (i.e. light yellow powder), moisture, ash, heavy metals and microbial
counts, which all remained within specifications during the testing period.
Parameter
Batch number
C20151209 C20160606(1) C20170106 C20170515 C20171009
Cadmium (Cd) < 0.01 mg/kg < 0.01 mg/kg < 0.01 mg/kg < 0.01 mg/kg < 0.01 mg/kg
Mercury (Hg) < 0.01 mg/kg < 0.01 mg/kg < 0.01 mg/kg 0.02 mg/kg 0.02 mg/kg
Ethanol < 0.5% < 0.5% < 0.5% < 0.5% < 0.5%
Microbiological
Total plate count 370 CFU/g 35 CFU/g 410 CFU/g 900 CFU/g < 10 CFU/g
Yeast and mould 210 CFU/g 20 CFU/g 60 CFU/g < 20 CFU/g < 20 CFU/g
Enterobacteriaceae – < 10 CFU/g < 10 CFU/g < 10 CFU/g < 10 CFU/g
E. coli (in 25 g) Negative Negative Negative Negative Negative
Salmonella (in 375 g) Negative Negative Negative Negative Negative
Staphylococcus
aureus (in 25 g)
Negative Negative Negative Negative Negative
NF: novel food; CFU: colony forming units.
(1): Batch of the NF that was used in the 90-day toxicity study (see Section 3.10.2).
Table 2: Total saponins, astragaloside I and ginsenoside Rb1 in the NF
Parameter
Batch number
20100621(1) C20150120(2) 20100824 C20140921
Total saponins 2.35% 2.68% 2.92% 2.0%
Ginsenoside Rb1 0.17% 0.10% 0.10% Not provided
Astragaloside I 0.054% 0.033% 0.039% Not provided
NF: novel food.
(1): Batch of the NF that was used in the 28-day toxicity study.
(2): Batch of the NF that was used in the bacterial reverse mutation test and in the in vitro mammalian cell gene mutation assay
(see Section 3.10.1).
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The Panel considers that, given the low moisture content of the NF, eventual degradation products
or microbial activity are unlikely to be of safety concern. Since the product parameters were
unchanged for six months under accelerated conditions the product can be expected to be stable for
up to 2 years.
3.5. Specifications
The specifications of the NF are indicated in Table 4.
The applicant informed that each batch of the NF will be subjected to a series of analytical quality
controls to ensure that all product specifications are met, including physicochemical parameters,
organoleptic characteristics, microbial counts, heavy metals and pesticide residues.
The Panel considers that the information provided on the specifications of the NF is sufficient and
does not raise safety concerns.
Table 3: Total saponin content of the NF during the stability testing
Date of analysis
Batch number
20100621 20100720 20100825
22/10/2010 2.35% 2.65% 2.92%
22/11/2010 2.39% 2.68% 2.84%
22/12/2010 2.37% 2.59% 2.88%
22/1/2011 2.41% 2.61% 2.86%
22/4/2011 2.43% 2.61% 2.93%
NF: novel food.
Table 4: Specifications of the NF
Description: The NF is a combination of an ethanol extract of the roots of Astragalus membranaceus (Fisch.)
Bunge and a hot water extract of the roots of Panax notoginseng (Burkill) F.H. Chen
Appearance: beige to light brown yellow powder
Parameter Specification Method of analysis
Total saponins 1.5–5.0% UV absorption (at 560  5 nm)
Ginsenoside Rb1 0.10–0.50% HPLC-UV
Astragaloside I 0.01–0.10% HPLC-ELSD
Carbohydrates ≥ 90% By calculation
Protein ≤ 4.5% Kjeldahl
Moisture ≤ 5.0% GB/T 14769 -1993
Ash ≤ 1.0% AOAC 942.05, 18th
Contaminants
Arsenic (As) ≤ 0.3 mg/kg ChP 2015, App. IXB (ICP-MS)
Microbiological
Total plate count ≤ 5,000 CFU/g ISO 4833-1
Total yeast and mould count ≤ 500 CFU/g FDA (BAM) Chapter 18, 8th Ed.
Enterobacteriaceae < 10 CFU/g ISO 21528-2:2004
E. coli Negative in 25 g ISO 7251:2005
Salmonella Negative in 375 g FDA (BAM) Chapter 5, 8th Ed.
Staphylococcus aureus Negative in 25 g GB 5009.22-2016
CFU: colony forming units; FDA-BAM: Food and Drug Administration’s Bacteriological Analytical Manual; GC–MS: gas
chromatography–mass spectrometry; HPLC: high-performance liquid chromatography; ICP-MS:inductively coupled plasma mass
spectrometry; UV: ultraviolet; ELSD: evaporative light scattering detector.
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3.6. History of use of the NF and/or of its source
3.6.1. History of use of the source of the NF
Both plants A. membranaceus and P. notoginseng have a long history of use in humans, especially
in China.
According to the information provided, A. membranaceus has a recorded history of use of over
2,000 years (Khan and Abourashed, 2009). Traditionally, it has mainly been used as raw dried root,
honey-cured root or as aqueous decoction, although steeping in ethanol has also been described
(Reid, 1995; Khan and Abourashed, 2009). Daily doses of the root are reported to range from 9 to 30
g, with more than 60 g in some cases (Duke and Ayensu, 1985; Leung, 1995; Leung and Foster, 1996;
Zhu, 1998b; Yu et al., 2007).
Documented use of P. notoginseng dates back to the 16th century and its cultivation in certain
areas has been reported to exceed 1,000 years, with current production in China of approximately
2,000 tonnes per year (Dong et al., 2003). Typical total daily doses range from approximately 3 to
15 g of roots for a decoction or 1–5 g of root as a ground powder. The use of ethanolic extracts was
also reported (Bensky and Gamble, 1986; Zhu, 1998a; Dharmananda, 2004; Wang et al., 2006; Reid,
1987).
The Panel notes that extensive literature searches performed by UCT Prague retrieved 13,581 and
8,116 scientific articles for A. membranaceus and P. notoginseng, respectively, demonstrating that
these species have been extensively studied.
3.6.2. History of use of the NF
According to the information provided by the applicant, the NF is already marketed as a food
supplement in a number of countries worldwide (e.g. Australia, Brazil, Canada, India).
Sales data have been provided for individual countries for the years 2011, 2012 and 2013
(confidential information).
3.7. Proposed uses and use levels
3.7.1. Target population
The target population proposed by the applicant is the general adult population, except pregnant
women.
3.7.2. Proposed uses and use levels
The applicant proposed to use the NF as a food supplement.
Following a request for clarification, the applicant proposed an amount of 50 mg per portion and a
maximum daily amount of 350 mg of the NF.
3.8. Absorption, distribution, metabolism and excretion (ADME)
The applicant has not provided any toxicokinetic studies that were performed with the NF.
A number of animal studies were submitted, which investigated the absorption, distribution,
metabolism and excretion of various saponins. The Panel considers that the studies provided are of
limited relevance for the safety assessment of the NF.
3.9. Nutritional information
The applicant provided a nutritional analysis of the NF, which indicates that the NF mainly consists
of carbohydrates (about 90%), moisture (about 5%), protein (2–5%), fat (about 1%) and ash. The
applicant pointed out that some variation can be expected concerning the nutrients in the NF, given
the nature of the starting material and its susceptibility to varying weather conditions.
Taking into account the proposed conditions of use (i.e. max. 350 mg/day), the Panel considers
that the consumption of the NF is not nutritionally disadvantageous.
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3.10. Toxicological information
The roots of A. membranaceus have been reported to contain the non-proteinogenic amino acid
L-canavanine (Thorne Research Inc, 2003; Khan and Abourashed, 2009). L-Canavanine is an
antinutrient that is structurally related to L-arginine. Owing to this similarity, in organisms that consume
L-canavanine, it is mistakenly incorporated into their own proteins in place of L-arginine, leading to the
production of structurally aberrant proteins. L-Canavanine has been suspected of being associated with
systemic lupus erythematosus (SLE) activation (Alcocer-Varela et al., 1985; Morimoto et al., 1990).
L-Canavanine is found in many legumes where it acts as a nitrogen-storing metabolite and is part of
the plant’s chemical defence. For example, L-canavanine accounts for up to 5% of the dry weight in
the jack bean seed (Canavalia ensiformis), 2.4% in the alfalfa plant (Medicago sativa) and up to 2.5%
in sword bean (Canavalia gladiate) (Rosenthal, 2001; Bence and Crooks, 2003). Following an EFSA
request to provide information on the content of L-canavanine in the NF, the applicant submitted a
certificate of analysis for one batch of the NF in which L-canavanine was detected at a concentration of
0.67 mg/g. The Panel notes that the amount of L-canavanine at the proposed conditions of use for the
NF (i.e. 350 mg per day) would be 0.23 mg/day. The Panel considers L-canavanine in the NF unlikely
to be of safety concern at the proposed conditions of use.
P. notoginseng has been reported to contain the non-proteinogenic amino acid L-dencichin
(oxalyldiaminopropionic acid (ODAP)) (Wang et al., 2006), which is a structural analogue of the
neurotransmitter glutamate. L-Dencichin is a neurotoxin responsible for lathyrism, a motor neuron
degeneration syndrome. Lathyrism may be induced by consumption of the seeds (if consumed at high
enough amounts) of the legume Lathyrus sativus (grass pea), which is a staple food in some areas of
the world and which has been reported to contain L-dencichin at concentrations up to 0.7% (Xu et al.,
2017). Following an EFSA request to provide information on the content of L-dencichin in the NF, the
applicant submitted a certificate of analysis for one batch of the NF in which L-dencichin was not
detected. No LOD was provided. However, information was provided on the method that was used for
the analysis (Dezhuang et al., 1998). From the information provided, the limit of quantification (LOQ)
for L-dencichin is at a level of about 0.17% for the method used. Taking into consideration the
maximum proposed use level of 350 mg NF/day, and assuming an L-dencichin concentration at the
LOQ (i.e. 0.17%) in the P. notoginseng fraction (i.e. < 50% in the NF), this would correspond to about
0.3 mg L-dencichin/day. The Panel considers L-dencichin in the NF unlikely to be of safety concern at
the proposed conditions of use.
3.10.1. Genotoxicity
The applicant provided a bacterial reverse mutation assay (Zin, 2016, unpublished study report)
and an in vitro mammalian cell gene mutation assay (Ruslan et al., 2016, unpublished study report),
which were both performed with batch #C20150120 of the NF. This batch contains 2.68% total
saponins, 0.033% astragaloside I and 0.10% ginsenoside Rb1 (see also Table 2).
The bacterial reverse mutation test (Zin, 2016, unpublished study report) was performed in
compliance with good laboratory practice (GLP) and following OECD Test Guideline (TG) 471. The test
was carried out with Salmonella Typhimurium strains TA98, TA100, TA1535, TA1537 and Escherichia
coli strain WP2 uvrA, using the pre-incubation method in the presence and in the absence of an
exogenous metabolic activation system (i.e. S9-mix). In order to evaluate the cytotoxicity of the test
item a dose-finding test was performed with the five strains mentioned above, with and without
metabolic activation, using the following five concentrations of the NF dissolved in water: 313, 625,
1,250, 2,500 and 5,000 lg/plate. There was no sign of cytotoxicity and no precipitation of the test
material was observed at any concentration. Thus, the main test was performed using the same
concentrations. Positive and negative controls were included. The NF induced no biologically relevant
increase in the number of revertant colonies compared with the negative controls for all strains, in the
presence and absence of S9-mix, in the dose finding test and the main test.
The in vitro mammalian cell gene mutation test using the hypoxanthine-guanine phosphoribosyl
transferase (Hprt) gene (Ruslan et al., 2016, unpublished study report) was performed in compliance
with GLP. According to the applicant, the test was conducted in accordance with OECD TG 476.
However, the Panel notes that the NF was only tested in the absence and not in the presence of an
exogenous metabolic activation system (S9-mix) in the main experiment, which is considered a
relevant deviation. No rationale could be provided by the applicant for this deviation. In the absence of
activation, the NF did not induce an increase in the number of gene mutations in mammalian cells.
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Following an EFSA request, and in accordance with the EFSA recommendations for genotoxicity
testing (EFSA Scientific Committee, 2011), the applicant submitted two in vitro mammalian cell
micronucleus tests following OECD TG 487. As per the EFSA request, one micronucleus test per plant
extract was carried out.
The micronucleus test (Vedic Lifesciences, 2019a, Study Nr. 190503/NL/PC, unpublished study
report), submitted for the P. notoginseng extract, was performed with a batch (i.e. #20170702) that
contained 1.08% total saponins and 0.31% ginsenoside Rb1. The test, which followed OECD TG 487,
was carried out in cultured mammalian CHO-K1 cells. In order to evaluate the cytotoxicity of the test
item, the cells were exposed to the extract (dissolved in water and diluted with culture medium) at
concentrations of 310 lg/mL, 620 lg/mL, 1,250 lg/ml, 2,500 lg/mL and 5,000 lg/mL either for 30 h
in the absence of an exogenous metabolic system (S9-mix) or for 3 h in the presence or absence of
S9-mix. As the cytotoxicity even at the highest concentration of 5,000 lg/mL was less than 40%, the
study coordinators decided to use the following four concentrations of the extract in the main
experiment: 620, 1,250, 2,500 and 5,000 lg/mL. In the main test, the cytotoxicity at the highest
concentration of 5,000 lg/mL for 30 h without S9-mix was 35.9%. After short-term exposure to this
concentration in the presence of metabolic activation, the cytotoxicity was 38.5%, while without
metabolic activation it was 27.8%. Appropriate positive controls were used as per OECD TG 487 and
an adequate response was seen. Micronuclei were manually scored for at least 2,000 cells per
concentration. Compared to the vehicle control, there were no statistically significant differences in the
number of micronuclei at any tested concentration with and without metabolic activation.
Another micronucleus test was submitted (Vedic Lifesciences, 2019b; Study Nr. 190502/NL/PC,
unpublished study report), which assessed the clastogenic/aneugenic potential of the
A. membranaceus extract. The tested batch (i.e. #20180225) contained 3.1% total saponins and
0.12% astragaloside I. Also this test, which followed OECD TG 487, was carried out in cultured
mammalian CHO-K1 cells. In order to evaluate the cytotoxicity of the test item, the cells were exposed
to the extract (dissolved in water and diluted with culture medium) at concentrations of 310 lg/mL,
620 lg/mL, 1,250 lg/mL, 2,500 lg/mL and 5,000 lg/mL for 30 h in the absence or for 3 h in the
presence and absence of an exogenous metabolic system (S9-mix). The observed toxicity was up to
29% after exposure for 30 h without S9-mix. After exposure for 3 h with and without metabolic
activation, the cytotoxicity amounted to 24% and 18.1%, respectively. As the observed toxicity was
less than 35% at any concentration with or without S9-mix, the study coordinators decided to use the
following three concentrations of the extract in the main experiment: 500, 1,500 and 5,000 lg/mL. In
the main test, the cytotoxicity at the highest concentration of 5,000 lg/mL for 30 h without S9-mix
was 28.5%. After short-term exposure to this concentration in the presence of metabolic activation the
cytotoxicity was 30.5%, while without metabolic activation it was 29.4%. Appropriate positive controls
were used as per OECD TG 487 and an adequate response was seen. Micronuclei were manually
scored for at least 2,000 cells per concentration. Compared to the vehicle control there were no
statistically significant differences in the number of micronuclei at any tested concentration with and
without metabolic activation.
The Panel concludes that the studies provided do not raise concerns for genotoxicity of the NF.
3.10.2. Subacute and subchronic toxicity
The applicant provided a 28-day oral toxicity study (Pasics Szakonyine, 2011, unpublished study
report) conducted in compliance with GLP and in accordance with OECD TG 407. Twenty Wistar rats (n
= 10 per sex) per group were administered by gavage 0, 100, 300 or 1,000 mg/kg body weight (bw)
per day of the NF for 28 days. The batch (#20100621) that was used in this study contained 2.35%
total saponins, 0.17% ginsenoside Rb1 and 0.054% astragaloside I (see also Table 2). The test item
was prepared daily by suspending the NF in 1%-aqueous methylcellulose vehicle.
There was no mortality during the study period. No clinical signs or abnormalities in behaviour,
motor activity or general health were observed in control or treated animals. No relevant differences in
body weight or body weight gain or feed consumption were observed among the groups.
A number of statistically significant differences in haematology and clinical chemistry between
controls and animals administered the NF were observed (available in a file annexed to the scientific
opinion under ‘Supporting information’). The number of neutrophils significantly increased in all groups
receiving the NF. In male rats, the number of basophils was reduced in the mid-dose group. In
females, white blood cells (WBC) and lymphocytes were reduced in the low- and mid-dose groups and
in the mid- and high-dose groups, respectively. Furthermore, in female rats, mean corpuscular volume
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(MCV) was reduced in the low-dose group, mean corpuscular haemoglobin concentration (MCHC) was
decreased in the mid-dose group and platelets were increased in the low-dose group. Activated partial
thromboplastin time (APTT) was increased in the high-dose group compared to the control group. The
serum concentration of phosphorus increased with dose in both sexes, being statistically significant in
the high-dose group of males and in the mid- and high-dose groups for females.
Absolute and relative organ weights were not different between the groups, except for a higher
testes to brain weight ratio in the low-dose males and a lower absolute and relative to body weight
kidney weight in the high-dose males. However, the differences were small and considered biologically
not relevant. No relevant dose-related histopathological findings were observed.
The applicant provided a repeated dose 90-day oral toxicity study (Upadhyaya and Wang, 2017,
unpublished study report) which was conducted in accordance with OECD TG 408 and in compliance
with GLP.
Wistar rats (n = 10/group and sex) of 6–8 weeks of age were randomly allocated to one of six
groups, which were administered the NF daily by gavage for 90 consecutive days at dosages of 0 mg/kg
bw per day (control group), 100 mg/kg bw per day, 300 mg/kg bw per day or 1,000 mg/kg bw per day.
The study included two additional groups (i.e. recovery groups) that received 0 mg/kg bw per day
(controls) or 1,000 mg/kg bw per day, respectively, for 90 days, and thereafter 0 mg/kg bw per day for
an additional 2-week period (i.e. recovery period). The batch (#C20160606) that was used in this study
contained 3.79% total saponins, 0.17% ginsenoside Rb1 and 0.028% astragaloside I (see also Table 1).
The test item was prepared (with water as vehicle) every day before administration.
None of the animals died in the course of the study. No treatment-related clinical signs were
observed in any of the animals throughout the study. Ophthalmological and neurobehavioural
examinations of the animals did not reveal any differences between the groups. No treatment-related
changes in body weight or body weight gain were observed. However, compared to the controls, feed
consumption was lower in males in the low-dose group until day 78 and it was higher in females in the
mid- and high-dose groups for most of the study duration. On day 91 (day 105 for the recovery
groups), animals were subjected to necropsy and a gross pathological examination was performed. No
changes were found in gross pathology.
A number of statistically significant differences in clinical chemistry between controls and animals
exposed to the NF were observed (A summary of the results can be found in the online version of this
output under the ‘Supporting information’ section: https://doi.org/10.2903/j.efsa.2020.6099). Serum
cholesterol and triglyceride concentrations were increased in males and females. Cholesterol was
increased in the high-dose group in the males and in females in all the groups that were administered
the NF. Triglycerides were increased in the mid- and high-dose groups for both sexes. Increases were
also observed for alanine amino transferase (ALT) (in males of the high-dose group and in females in
all the treatment groups) and alkaline phosphatase (ALP) (in males of the high-dose group and in
females in the low-dose group). Aspartate amino transferase (AST) was increased in females only, i.e.
in the low- and mid-dose groups. Furthermore, lactate dehydrogenase (LDH) was increased in both
sexes, in males in all treatment groups and in females in the high-dose group. In males, phosphorous
was increased in the mid- and high-dose groups and remained higher (statistically significant) also
after the recovery period. In females, succinate dehydrogenase (SDH) and total protein were increased
(SDH in the mid- and high dose groups, total protein in all groups receiving the NF).
A number of statistically significant findings were observed for absolute and relative organ weights,
but the observed changes were small, often not dose-related and in many cases a result of rather low
values in the control groups (with respect to historical controls). No differences were seen in urinalysis.
The Panel notes that a considerable number of changes were observed in clinical chemistry,
including markers of liver and kidney toxicity. Even though the size of individual changes was rather
small and within historical ranges, the effects were seen consistently in both sexes, were often dose-
related and, in the case of phosphorus, also observed after the recovery period. The Panel considers
that taken together, the findings imply a potentially adverse effect of the NF. The Panel also considers
that taking into account the magnitude of the effects seen, the overall lowest observed adverse effect
level (LOAEL) is to be set at 300 mg/kg bw per day. Consequently, the Panel considers the lowest dose
tested in the study, i.e. 100 mg/kg bw per day, as the overall no observed adverse effect level
(NOAEL).
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3.10.3. Human data
The applicant did not provide any human studies performed with the NF nor were there any human
studies with the NF retrieved by extensive literature searches.
3.11. Allergenicity
The Panel notes the protein content (2–5%) of the NF and, thus, the potential of the NF to elicit
allergic reactions.
The literature searches carried out by the applicant and by the EFSA contractor (UCT Prague) did
not retrieve any studies reporting incidents of allergenicity to the NF or to A. membranaceus, one of
the two plants that is used to produce the NF.
With respect to P. notoginseng, the applicant submitted one review (Dharmananda, 2004), which
described 19 case reports of allergic reactions to Sanqi (i.e. dried tuber of P. notoginseng). No further
information on the allergenicity of P. notoginseng was provided.
The Panel notes the limited epidemiological data reported on one of the two plants that is used to
produce the NF.
Overall, taking into account the long history of use of both plants (i.e. A. membranaceus and
P. notoginseng) that are used to produce the NF, the Panel considers that the risk of allergic reactions
to the NF for the general population is unknown but expected to be low.
4. Discussion
The NF is a mixture of the root extracts of A. membranaceus and P. notoginseng, and contains
marker compounds within a specified range (i.e. 1.5–5% total saponins, 0.1–0.5% ginsenoside Rb1
and 0.01–0.1% astragaloside I). The Panel considers that the information provided on the composition
of the NF and the production process is sufficient and does not raise safety concerns.
The applicant proposed to use the NF as a food supplement for the general adult population (with
the exception of pregnant women) at a maximum daily amount of 350 mg. The Panel considers that,
taking into account the proposed conditions of use, the consumption of the NF is not nutritionally
disadvantageous.
The provided genotoxicity studies do not raise concerns for genotoxicity of the NF. In view of the
maximum daily amount proposed for the NF, contribution of pesticides or contaminants is not of
toxicological relevance.
Based on the findings of a subchronic toxicity study, supported by a subacute toxicity study, the
Panel identified the overall NOAEL of the NF at 100 mg/kg bw per day.
The Panel considers an uncertainty factor (UF) of 200 appropriate, in order to account for inter-
and intra-species variability (UF 10 9 10) and for the lack of chronic toxicity data (additional UF of 2).
The application of this UF to the NOAEL results in a safe intake level for the NF of 0.5 mg/kg bw per
day. Considering a standard bodyweight of 70 kg for adults (EFSA Scientific Committee, 2012), this
level corresponds to a maximum daily intake of 35 mg NF for the target population, i.e. adults
excluding pregnant women.
5. Conclusions
The Panel concludes that the NF, i.e. a botanical extract derived from both P. notoginseng and
A. membranaceus roots (AstraGinTM), is safe at an intake level of 0.5 mg/kg bw per day. This level
corresponds to a maximum intake of 35 mg/day for the target population, i.e. adults excluding
pregnant women.
The Panel could not have reached the conclusion on the safety of the NF under the proposed
conditions of use without the toxicological data for which protection of proprietary data was requested
by the applicant (Pasics Szakonyine, 2011; Zin, 2016; Upadhyaya and Wang, 2017; Vedic Lifesciences,
2019a,b).
Steps taken by EFSA
1) Letter from the European Commission to the European Food Safety Authority with the
request for a scientific opinion on the safety of a botanical extract derived from Panax
notoginseng and Astragalus membranaceus. Ref. Ares(2018)5414664, dated 22 October
2018.
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2) On 22 October 2018, EFSA received a valid application from the European Commission on a
botanical extract derived from Panax notoginseng and Astragalus membranaceus (AstraGinTM)
as a novel food, which was submitted by NuLiv Science (US), and the scientific evaluation
procedure started.
3) On 6 March 2019, EFSA requested the applicant to provide additional information to
accompany the application and the scientific evaluation was suspended.
4) On 30 August 2019, additional information was provided by the applicant and the scientific
evaluation was restarted.
5) On 11 November 2019, EFSA requested the applicant to provide additional information to
accompany the application and the scientific evaluation was suspended.
6) On 23 January 2020, additional information was provided by the applicant and the scientific
evaluation was restarted.
7) During its meeting on 24 March 2020, the NDA Panel, having evaluated the data, adopted a
scientific opinion on the safety of a botanical extract derived from Panax notoginseng and
Astragalus membranaceus as a NF pursuant to Regulation (EU) 2015/2283.
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Abbreviations
ADME absorption, distribution, metabolism and excretion
ALP alkaline phosphatase
ALT alanine amino transferase
APTT activated partial thromboplastin time
AST aspartate amino transferase
bw body weight
CFU colony forming units
ELSD evaporative light scattering detector
FDA-BAM Food and Drug Administration’s Bacteriological Analytical Manual
GC-MS gas chromatography–mass spectrometry
GLP good laboratory practice
GMP good manufacturing practice
HACCP hazard analysis and critical control points
HPLC high-performance liquid chromatography
HPRT hypoxanthine-guanine phosphoribosyl transferase gene
ICP-MS inductively coupled plasma mass spectrometry
LDH lactate dehydrogenase
LOAEL lowest observed adverse effect level
LOD limit of detection
LOQ limit of quantification
MCHC mean corpuscular haemoglobin concentration
MCV mean corpuscular volume
MF mutation frequency
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NF novel food
NOAEL no observed adverse effect level
ODAP oxalyldiaminopropionic acid
OECD Organisation for Co-operation and Development
RNA ribonucleic acid
SDH succinate dehydrogenase
SLE systemic lupus erythematosus
TG test guidelines
UF uncertainty factor
UV ultraviolet
WBC white blood cells
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